9 articles
The 2026 financing rounds and listing steps by Chinese brain-computer interface companies verified by InsideBCI, from BrainCo's RMB 2 billion round to Neuracle's STAR Market application, with amounts, lead investors and sources. Updated as new rounds are announced.
NeuroXess, Nanochap and Shanghai's Zhudong Technology announced rounds totalling RMB 1.664 billion between 28 October and 4 November 2026, with state-backed funds among the investors, while StairMed filed for A-share pre-listing tutoring. The 'over RMB 3 billion in a week' figure in Chinese coverage adds StairMed's financing since July.
Shanghai brain-computer interface company NeuroXess announced a RMB 700 million Series B round on 28 October 2026, co-led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital and described by 36Kr as dominated overall by state capital. The money will fund the multicentre registration trial of its implant for people with quadriplegia, a factory in Jiangxi and next-generation products.
NeuroXess (脑虎科技), the Shanghai brain-computer interface developer, disclosed on 30 September 2026 that a man with a C4 spinal cord injury, implanted in April 2026 with its fully implanted, fully wireless Triple-Full system, used it to draw a sketch and enter prompts, from which a large AI model generated design options and one was 3D-printed as a figurine. Using AI smart glasses and NeuroXess's XessOS software, he also adjusted his hospital bed and switched lights and household devices by confirming his intent. NeuroXess describes the work as clinical exploration and released no speed or accuracy figures. The Triple-Full system is in a registration trial led at Huashan Hospital that began on 7 July 2026, with an estimated 32 participants and primary completion estimated for 30 January 2027, and entered the National Medical Products Administration's innovative device review in July.
China's Ministry of Industry and Information Technology named brain-computer interfaces among six future industries in a State Council Information Office press conference on 26 August 2026, alongside quantum technology, biomanufacturing, hydrogen and nuclear fusion energy, embodied intelligence, and 6G. MIIT's draft standards guide, published for comment on 24 August, targets at least 40 BCI standards by 2028 and at least 80 by 2030.
In one month, four separate Chinese brain-computer interface programmes each produced a public result. Neuracle wrote the world's first commercial prescription for an invasive BCI at Huashan Hospital on 13 July. NeuroXess ran a two-patient cross-city Chinese chess demonstration between Shanghai and Nanchang. StairMed's investigational trial put three quadriplegic patients into paid remote work. And at the World AI Conference in Shanghai, a paralysed fine-arts graduate from Shenzhen demoed a mind-controlled wheelchair he had built himself with LLM-assisted DIY.
On 20 July 2026, at the World Artificial Intelligence Conference in Shanghai, StairMed disclosed that its cortex-penetrating invasive BCI clinical trial at Huashan Hospital has now reached 18 cumulative implants since March 2025. The Shanghai firm co-founded by Zhao Zhengtuo and Xue Li at the Chinese Academy of Sciences' Center for Excellence in Brain Science demonstrated a patient three months post-op controlling a wheelchair by thought and hitting 6.19 bits per second on a cursor task, alongside a live journalist test at 4.9 bits per second with a finger.
The Chinese neural interface company begins construction of the country's first dedicated manufacturing facility for implantable brain-computer interfaces in Nanchang, signaling a shift from lab to production line.
Chinese BCI company NeuroXess has surpassed human trial milestones, positioning itself as a direct competitor to Neuralink in the global neural interface market.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.